FDA Clears Procept's Robotic Surgical Platform for 'Aquablation' Therapy

It uses a heat-free waterjet.

Screenshot 2024 08 27 At 10 56 24 Am
PROCEPT BioRobotics

PROCEPT BioRobotics announced FDA 510(k) clearance of its platform, the HYDROS Robotic System, which features FirstAssist AI treatment planning, advanced image guidance, robotic resection, and a streamlined workflow.

The HYDROS Robotic System represents the next evolution in the delivery of Aquablation therapy, combining technology with user-friendly features designed to deliver better clinical outcomes for patients and healthcare providers.

Key Features of the Fully Integrated HYDROS Robotic System Include:

  • AI-Powered Treatment Planning: FirstAssist AI, built from a library of real-world Aquablation therapy procedures, uses advanced image recognition software to accurately identify critical anatomy on ultrasound and suggest an optimal treatment plan for each patient.
  • Advanced Image Guidance: The system integrates next-generation ultrasound imaging, digital cystoscopy, and dual high-definition touchscreens providing enhanced visualization of the anatomy and simultaneous viewing of ultrasound and cystoscopy images.
  • Robotic Resection: Using a heat-free waterjet, the robot executes the surgeon-defined treatment plan to resect obstructive tissue while protecting critical anatomy. This enables efficient and predictable waterjet execution, standardizing the operative experience across a wide range of prostate sizes and shapes.
  • Streamlined Workflow: Designed to improve the surgeon and staff experience at every stage of the Aquablation therapy procedure. With a single-footprint, the integrated tower facilitates efficient operating room setup and turnover. The adjustable touchscreen improves surgeon ergonomics with midline placement, and the instinctive software interface simplifies procedural workflow.
More in Surgical